Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004.
BACKGROUND
Low-density lipoprotein (LDL) cholesterol is a major contributor to coronary heart disease and the primary target of cholesterol-lowering therapy. Substantial disparities in cholesterol control exist nationally, but it is unclear how these patterns vary locally.


METHODS
We estimated the prevalence, awareness, treatment, and control of high LDL cholesterol using data from a unique local survey of New York City's diverse population. The New York City Health and Nutrition Examination Survey 2004 was administered to a probability sample of New York City adults. The National Health and Nutrition Examination Survey 2003-2004 was used for comparison. High LDL cholesterol and coronary heart disease risk were defined using National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines.


RESULTS
Mean LDL cholesterol levels in New York City and nationally were similar. In New York City, 28% of adults had high LDL cholesterol, 71% of whom were aware of their condition. Most aware adults reported modifying their diet or activity level (88%), 64% took medication, and 44% had their condition under control. More aware adults in the low ATP III risk group than those in higher risk groups had controlled LDL cholesterol (71% vs 33%-42%); more whites than blacks and Hispanics had controlled LDL cholesterol (53% vs 31% and 32%, respectively).


CONCLUSIONS
High prevalence of high LDL cholesterol and inadequate treatment and control contribute to preventable illness and death, especially among those at highest risk. Population approaches - such as making the food environment more heart-healthy - and aggressive clinical management of cholesterol levels are needed.
Upadhyay
Ushma D
UD
Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene, 125 Worth St, Room 315, CN No. 6, New York, NY 10013, USA. ewaddell@health.nyc.gov
Waddell
Elizabeth Needham
EN
Young
Stephanie
S
Kerker
Bonnie D
BD
Berger
Magdalena
M
Matte
Thomas
T
Angell
Sonia Y
SY
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001364:Awareness; D008078:Cholesterol, LDL / Q000097:blood*; D018752:Diet, Fat-Restricted / Q000379:methods*; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL
N Engl J Med. 2007 Jun 7;356(23):2388-98
17554120
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32
15358046
Clin Investig. 1992 Mar-Apr;70(3-4):263-8
1521040
Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120
18512336
Circulation. 1991 Jan;83(1):356-62
1984895
Ann Epidemiol. 2007 Jul;17(7):548-55
17395483
Ann Pharmacother. 2008 Sep;42(9):1208-15
18648016
JAMA. 2000 Jul 19;284(3):311-8
10891962
Diabetes Care. 2009 Jan;32(1):57-62
19114627
Perm J. 2007 Summer;11(3):12-20
21461107
J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6
15172426
JAMA. 2005 Oct 12;294(14):1773-81
16219880
N Engl J Med. 2007 Oct 11;357(15):1477-86
17928595
MMWR Morb Mortal Wkly Rep. 2007 Jun 22;56(24):604-8
17585290
Am J Public Health. 2009 Jan;99(1):152-9
18556616
Healthy People 2010 Stat Notes. 2001 Jan;(20):1-10
11676466
Ann Intern Med. 2009 Jul 21;151(2):129-34
19620165
Clin Chem. 1972 Jun;18(6):499-502
4337382
Baillieres Clin Endocrinol Metab. 1994 Jul;8(3):629-60
7980350
Int J Epidemiol. 2008 Oct;37(5):966-77
18540026
Prev Chronic Dis. 2006 Jul;3(3):A94
16776895
Am J Epidemiol. 2008 Apr 15;167(8):917-24
18304960
Am J Cardiol. 2003 Jul 1;92(1):79-81
12842255
N Engl J Med. 2007 Oct 11;357(15):1543-5
17928603
Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):46-53
20031787